Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

KDS2010

Phase 2Small molecule

NNeuroBiogen Co., Ltd

KDS2010 is one of 48 small molecule programs targeting Obesity. It is currently in Phase 2.

2

Indications

2

Total Trials

2

Active Trials

47

Competitors

Pipeline

Status by Indication[3][1]

Indication

ObesityRecruiting

Mild Cognitive Impairment (MCI)Recruiting

ObesityPhase 2

Recruiting

Mild Cognitive Impairment (MCI)Phase 2

Recruiting

Competition

Competitive Landscape

190 competitors in Obesity

#DrugCompanyPhaseTrials

Synthroid

IInstitut Jerome Lejeune

Vivia

SSpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

IBI362

Innovent Biologics (Suzhou) Co. Ltd.

Eloralintide

Mibavademab

Ribupatide

Elecoglipron

Aleniglipron

GGasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics

Avapro

Amidate

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Obesity

NCT07009171

Q4 2027

Phase 2Recruiting

Mild Cognitive Impairment (MCI)

NCT07027072

Clinical

Trials by Indication[1]

Obesity1 trial

A Randomized, Double-blind, Placebo-controlled, Dose Finding, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of KDS2010 in Overweight or Obese Patients

Recruiting·NNeuroBiogen Co., Ltd·Phase 2·NCT07009171·75 enrolled

Mild Cognitive Impairment (MCI)1 trial

A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Phase 2a Clinical Trial to Evaluate the Efficacy and Safety of KDS2010 in Patients With Alzheimer's Disease With Mild Cognitive Impairment and Mild Dementia Due to Alzheimer's Disease

Recruiting·NNeuroBiogen Co., Ltd·Phase 2·NCT07027072·114 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for KDS2010. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — KDS2010 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for KDS2010. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — NeuroBiogen Co., Ltd company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: NNeuroBiogen Co., Ltd

Related News